Fluorodeoxyglucose positron emission tomography fails to detect distant metastases at initial staging of melanoma patients with metastatic involvement of sentinel lymph node

British Journal of Dermatology

Volumn 164, Issue 6, 2011, Pages 1235-1240

  Wagner, T ^a   Meyer, N ^b   Zerdoud, S ^c   Julian, A ^a   Chevreau, C ^c   Payoux, P ^a   Courbon, F ^c  

^a CHU PURPAN   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE; GLUCOTEP; UNCLASSIFIED DRUG;

ARTICLE; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISTANT METASTASIS; FEMALE; HUMAN; LYMPH NODE METASTASIS; MALE; MELANOMA; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY;

DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHATIC METASTASIS; MALE; MELANOMA; NEOPLASM METASTASIS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 79957602027     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10247.x     Document Type: Article

References (24)

1. Tsao H, Atkins MB, Sober AJ,. Management of cutaneous melanoma. N Engl J Med 2004; 351: 998-1012.
2. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-206.
3. Phan GQ, Messina JL, Sondak VK, Zager JS,. Sentinel lymph node biopsy for melanoma: indications and rationale. Cancer Control 2009; 16: 234-9.
4. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006; 355: 1307-17. (Pubitemid 44465459)
5. Manola J, Atkins M, Ibrahim J, Kirkwood J,. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 2000; 18: 3782-93.
6. Belhocine TZ, Scott AM, Even-Sapir E, et al. Role of nuclear medicine in the management of cutaneous malignant melanoma. J Nucl Med 2006; 47: 957-67. (Pubitemid 46939948)
7. Brady MS, Akhurst T, Spanknebel K, et al. Utility of preoperative [(18)]F fluorodeoxyglucose-positron emission tomography scanning in high-risk melanoma patients. Ann Surg Oncol 2006; 13: 525-32.
8. Rinne D, Baum RP, Hor G, Kaufmann R,. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 1998; 82: 1664-71. (Pubitemid 28208915)
9. Stas M, Stroobants S, Dupont P, et al. 18-FDG PET scan in the staging of recurrent melanoma: additional value and therapeutic impact. Melanoma Res 2002; 12: 479-90. (Pubitemid 35264725)
10. Fuster D, Chiang S, Johnson G, et al. Is 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma? J Nucl Med 2004; 45: 1323-7. (Pubitemid 47618530)
11. Wagner JD, Schauwecker D, Davidson D, et al. Inefficacy of F-18 fluorodeoxy-d-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer 2005; 104: 570-9. (Pubitemid 41022815)
12. Singh B, Ezziddin S, Palmedo H, et al. Preoperative 18F-FDG-PET/CT imaging and sentinel node biopsy in the detection of regional lymph node metastases in malignant melanoma. Melanoma Res 2008; 18: 346-52.
13. Horn J, Lock-Andersen J, Sjøstrand H, Loft A,. Routine use of FDG-PET scans in melanoma patients with positive sentinel node biopsy. Eur J Nucl Med Mol Imaging 2006; 33: 887-92. (Pubitemid 44127436)
14. Nieweg O, Valdés Olmos R,. Routine use of FDG-PET scans in melanoma patients with positive sentinel node biopsy. Eur J Nucl Med Mol Imaging 2007; 34: 602. (Pubitemid 46427004)
15. Miranda EP,. Futility of positron emission tomography and other modalities in the initial radiographic screening of patients with melanoma. Arch Surg 2006; 141: 1050. (Pubitemid 44583274)
16. Clark PB, Soo V, Kraas J, et al. Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma. Arch Surg 2006; 141: 284-8.
17. Hafner J, Schmid MH, Kempf W, et al. Baseline staging in cutaneous malignant melanoma. Br J Dermatol 2004; 150: 677-86. (Pubitemid 38586218)
18. Aloia TA, Gershenwald JE, Andtbacka RH, et al. Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma. J Clin Oncol 2006; 24: 2858-65. (Pubitemid 46630586)
19. Gold JS, Jaques DP, Busam KJ, et al. Yield and predictors of radiologic studies for identifying distant metastases in melanoma patients with a positive sentinel lymph node biopsy. Ann Surg Oncol 2007; 14: 2133-40. (Pubitemid 46988267)
20. Horn J, Sjøstrand H, Lock-Andersen J, Loft A,. [PET scanning for malignant melanoma and positive sentinel node diagnostics]. Ugeskr Laeger 2010; 172: 1126-30.
21. Constantinidou A, Hofman M, O'Doherty M, et al. Routine positron emission tomography and positron emission tomography/computed tomography in melanoma staging with positive sentinel node biopsy is of limited benefit. Melanoma Res 2008; 18: 56-60. (Pubitemid 351628057)
22. Mottaghy FM, Sunderkotter C, Schubert R, et al. Direct comparison of [18F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanoma. Eur J Nucl Med Mol Imaging 2007; 34: 1355-64. (Pubitemid 47312575)
23. Koskivuo IO, Seppanen MP, Suominen EA, Minn HR,. Whole body positron emission tomography in follow-up of high risk melanoma. Acta Oncol 2007; 46: 685-90. (Pubitemid 46911905)
24. Meier F, Will S, Ellwanger U, et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol 2002; 147: 62-70. (Pubitemid 34779439)